Cancer Care Ontario
Action Cancer Ontario | eClaims

Eligibility Form

Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer

This policy version is for trastuzumab biosimilars Herzuma, Kanjinti, Ogivri and Trazimera.

(This form must be completed before the first dose is dispensed.)

1. Patient Profile

* Surname: .....
* Given Name: .....
* OHIN: ..... * Chart Number: .....
* Postal Code: .....
* Height (cm): ..... * Weight (kg): .....
* BSA (m^2): ..... * Gender: ○ Male ○ Female ○ Other
* Date of Birth: ....
  Day Month Year
* Site:
* Attending Physician (MRP- Most Responsible Physician): .....

Requested Prior Approval ☐ Yes * Patient on Clinical Trial ○ Yes ○ No

Other (specify): .....

Specify Arm:
○ Standard of care arm ○ Experimental arm
○ Blinded / Unknown

Prior Approval Request

* Select the appropriate prior approval scenario:

- ○ 1-Unknown primary (submit pathology report and clinic note)
- ○ 2-Clinical document review (identify the patient history that needs to be reviewed against eligibility criteria in Additional Comments below)
- ○ 3-Regimen modification - schedule (complete questions a and b)
- ○ 4-Regimen modification - drug substitutions (complete questions a and c)
- ○ 5-Withholding a drug in combination therapy from start of treatment (complete questions d, e and f)
- ○ 6-Maintenance therapy delay (submit clinic note)
- ○ 7-Prior systemic therapy clinical trials (complete question g)
- ○ 8-Modification due to supply interruption/drug shortage
- ○ Other (specify)

.....

All relevant supporting documentation must be submitted at the time of prior approval. Documentation may include a pathology report, clinic note, and/or CT scans.

a. Co-morbidities / toxicity / justification:

.....

b. Intended regimen schedule: .....

c. Intended regimen: .....

d. Drug(s) to be held: .....

e. Rationale for holding drug(s): .....

f. Intention to introduce drug at a later date? ☐ Yes

g. Prior clinical trial identifier (e.g., NCT ID, trial name) and treatment description (e.g., arm, drug/regimen): .....

h. Anticipated date of first treatment: ..... Day ..... Month ..... Year

i. Additional comments:

2. Eligibility Criteria

The patient meets the following criteria:

Trastuzumab will be used for the treatment of second line HER2 positive metastatic breast cancer when given in combination with chemotherapy after previous exposure to trastuzumab based treatments in the metastatic setting

☐ Yes

3. Funded Dose

Please select one of the following regimens:

- ○ Trastuzumab loading dose of 8 mg/kg IV on Day 1 of the first cycle, followed by 6 mg/kg every 3 weeks until disease progression, unacceptable toxicity or withdrawal of consent
- ○ Trastuzumab loading dose of 4 mg/kg IV on Day 1 of the first cycle, followed by 2 mg/kg every week until disease progression, unacceptable toxicity or withdrawal of consent

4. Notes

a. Trastuzumab will not be funded:
   i. in combination with lapatinib for the second line treatment of HER2 positive metastatic breast cancer, and/or
   ii. if the patient has progressed on lapatinib for the second line treatment of HER2 positive metastatic breast cancer.

b. Funding of second line trastuzumab for HER2-positive metastatic breast cancer will be discontinued upon evidence of further disease progression.

c. Trastuzumab will continue to be funded if a patient had to discontinue their chemo treatment due to toxicity or intolerance. If disease progresses while on single agent trastuzumab, then further funding of trastuzumab will be discontinued.

d. The patient must have normal cardiac ejection fraction. Trastuzumab should not be given concurrently with an anthracycline.

e. For patients who have not received trastuzumab (adjuvant/metastatic) through the New Drug Funding Program, a photocopy of pathology report demonstrating HER2 overexpression must be submitted to Cancer Care Ontario. The report must state clearly the hospital, date of biopsy and the hospital pathology specimen of the original material used for the test.

5. FAQs

i. ***My patient is currently receiving trastuzumab (Herceptin). Can my patient stay on the reference biologic (i.e., trastuzumab (Herceptin))?***

Yes, patients currently on trastuzumab (Herceptin) or initiated on trastuzumab (Herceptin) before December 15, 2019 may continue with the reference biologic until their treatment course has ended.

Patients who are continuing treatment with trastuzumab (Herceptin) after December 15, 2019 must have an enrolment form and treatment claim(s) submitted in eClaims prior to December 15, 2019 to be eligible for continued reimbursement of trastuzumab (Herceptin).

ii. ***My patient is currently receiving trastuzumab (Herceptin). Can my patient be switched to a trastuzumab biosimilar for the remainder of their treatment cycles?***

At the discretion of the treating physician or based on individual hospital policy, patients currently on trastuzumab (Herceptin) may be switched over to a trastuzumab biosimilar for the remainder of the funded doses if a trastuzumab biosimilar is funded for the specific indication.

If the patient is already enrolled in an NDFP policy for trastuzumab, please re-enroll the patient in the updated trastuzumab enrolment form in order to submit treatments for trastuzumab biosimilars.

iii. ***Will the reimbursement rate be the same for all trastuzumab biosimilars?***

Reimbursement in eClaims will be adjudicated based on the Drug Identification Number (DIN) submitted, and may be unique to each trastuzumab biosimilar.

Any incentives or promotions accepted by hospitals related to purchase and/or selection decisions of trastuzumab will be interpreted as lowering the local acquisition cost of trastuzumab, and, consistent with other NDFP policies, are subject to recovery.

6. Supporting Documents

To ensure reimbursement of your claim, both the completed enrolment form and a copy of the required documentation (where applicable) must be submitted through CCO e-Claims.

Signature of Attending Physician (MRP-Most Responsible Physician): .....

....
Day Month Year